NSE BSE
divi s laboratories ltd stock

DIVI S LABORATORIES LTD Share Price

- - (%)
- NSE: DIVISLAB

DIVI S LABORATORIES LTD Share Price Update

As of the latest trading session, DIVI S LABORATORIES LTD share price is currently at 4790.6, which is up by 243.60 from its previous closing. Today, the stock has fluctuated between 4563.85 and 4810.00. Over the past year, DIVI S LABORATORIES LTD has achieved a return of 24.23 %. In the last month alone, the return has been 0.89 %. Read More...

DIVI S LABORATORIES LTD Performance

Day Range

Low4563.85 High4810.00
4519.80

52 Week Range

Low 3295.30 High 4670.00
4519.80

DIVI S LABORATORIES LTD Share Price

10940

532488

DIVISLAB

img img img img
No Data Available

Open Price

4570.95

Prev. Close

4547.00

Volume (Shares)

279117.00

Total traded value

12615.53

Upper Circuit

5001.70

Lower Circuit

4092.30

Note: The current prices & values are delayed, Login to your account for live updates.

DIVI S LABORATORIES LTD Fundamentals


(Standalone)

Market Cap (Cr) 127175.40
PE Ratio (TTM) 76.13
Book Value / Share 507.93
Beta 0.49
ROE 12.04%
EPS (TTM) 59.34
Dividend Yield 0.66%
Net Profit Qtr (Cr) 531.00

DIVI S LABORATORIES LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 2259.00
Operating Expense 1638.00
Net Profit 531.00
Net Profit Margin (%) 23.50
Earnings Per Share (EPS) 19.99
EBITDA 796.00
Effective Tax Rate (%) 24.14
Particulars DEC 2023 (Values in Cr)
Revenue 1808.00
Operating Expense 1412.00
Net Profit 358.00
Net Profit Margin (%) 19.80
Earnings Per Share (EPS) 13.50
EBITDA 585.00
Effective Tax Rate (%) 26.93
Particulars SEP 2023 (Values in Cr)
Revenue 1868.00
Operating Expense 1489.00
Net Profit 342.00
Net Profit Margin (%) 18.30
Earnings Per Share (EPS) 12.89
EBITDA 559.00
Effective Tax Rate (%) 26.29
Particulars JUN 2023 (Values in Cr)
Revenue 1730.00
Operating Expense 1332.00
Net Profit 345.00
Net Profit Margin (%) 19.94
Earnings Per Share (EPS) 12.99
EBITDA 571.00
Effective Tax Rate (%) 27.82
Particulars MAR 2023 (Values in Cr)
Revenue 1908.00
Operating Expense 1506.00
Net Profit 319.00
Net Profit Margin (%) 16.71
Earnings Per Share (EPS) 12.01
EBITDA 555.00
Effective Tax Rate (%) 31.83
Particulars MAR 2024 (Values in Cr)
Revenue 7665.00
Operating Expense 5870.00
Net Profit 1576.00
Net Profit Margin (%) 20.56
Earnings Per Share (EPS) 59.37
EBITDA 2511.00
Effective Tax Rate (%) 26.07
Particulars MAR 2023 (Values in Cr)
Revenue 7625.00
Operating Expense 5620.00
Net Profit 1808.00
Net Profit Margin (%) 23.71
Earnings Per Share (EPS) 68.11
EBITDA 2697.00
Effective Tax Rate (%) 23.19
Particulars MAR 2022 (Values in Cr)
Revenue 8879.82
Operating Expense 5314.55
Net Profit 2948.54
Net Profit Margin (%) 33.20
Earnings Per Share (EPS) 111.07
EBITDA 3987.72
Effective Tax Rate (%) 19.80
Particulars MAR 2021 (Values in Cr)
Revenue 6798.61
Operating Expense 4233.26
Net Profit 1954.72
Net Profit Margin (%) 28.75
Earnings Per Share (EPS) 73.63
EBITDA 2883.21
Effective Tax Rate (%) 25.61
Particulars MAR 2020 (Values in Cr)
Revenue 5310.57
Operating Expense 3687.14
Net Profit 1372.71
Net Profit Margin (%) 25.84
Earnings Per Share (EPS) 51.71
EBITDA 2005.30
Effective Tax Rate (%) 24.29
Particulars MAR 2024 (Values in Cr)
Book Value / Share 512.11
ROE % 12.15
ROCE % 16.41
Total Debt to Total Equity 0.00
EBITDA Margin 32.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 481.77
ROE % 14.89
ROCE % 19.31
Total Debt to Total Equity 0.00
EBITDA Margin 34.94
Particulars MAR 2022 (Values in Cr)
Book Value / Share 441.82
ROE % 28.16
ROCE % 34.96
Total Debt to Total Equity 0.00
EBITDA Margin 44.61
Particulars MAR 2021 (Values in Cr)
Book Value / Share 350.15
ROE % 23.90
ROCE % 31.97
Total Debt to Total Equity 0.00
EBITDA Margin 41.95
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.38
ROE % 19.30
ROCE % 25.29
Total Debt to Total Equity 0.01
EBITDA Margin 37.31
Particulars MAR 2024 (Values in Cr)
Book Value / Share 508.83
ROE % 12.04
ROCE % 16.27
Total Debt to Total Equity 0.00
EBITDA Margin 32.77
Particulars MAR 2023 (Values in Cr)
Book Value / Share 479.43
ROE % 14.82
ROCE % 19.27
Total Debt to Total Equity 0.00
EBITDA Margin 35.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 440.44
ROE % 28.13
ROCE % 35.01
Total Debt to Total Equity 0.00
EBITDA Margin 44.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 349.28
ROE % 23.57
ROCE % 31.55
Total Debt to Total Equity 0.00
EBITDA Margin 42.43
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.63
ROE % 19.21
ROCE % 25.17
Total Debt to Total Equity 0.01
EBITDA Margin 37.78
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3980.00
Total Assets 15470.00
Total Liabilities 15470.00
Total Equity 13571.00
Share Outstanding 265468580
Price to Book Ratio 6.75
Return on Assets (%) 10.34
Return on Capital (%) 11.79
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4214.00
Total Assets 14439.00
Total Liabilities 14439.00
Total Equity 12767.00
Share Outstanding 265468580
Price to Book Ratio 5.89
Return on Assets (%) 12.63
Return on Capital (%) 14.29
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2818.88
Total Assets 13374.71
Total Liabilities 13374.71
Total Equity 11728.18
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.13
Return on Capital (%) 25.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2156.03
Total Assets 10774.07
Total Liabilities 10774.07
Total Equity 9294.61
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.41
Return on Capital (%) 21.35
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 122.63
Total Assets 8535.70
Total Liabilities 8535.70
Total Equity 7309.92
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3961.00
Total Assets 15362.00
Total Liabilities 15362.00
Total Equity 13484.00
Share Outstanding 265468580
Price to Book Ratio 6.75
Return on Assets (%) 10.25
Return on Capital (%) 11.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4188.00
Total Assets 14352.00
Total Liabilities 14352.00
Total Equity 12705.00
Share Outstanding 265468580
Price to Book Ratio 5.89
Return on Assets (%) 12.59
Return on Capital (%) 14.23
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2803.68
Total Assets 13307.86
Total Liabilities 13307.86
Total Equity 11691.35
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.15
Return on Capital (%) 25.22
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2142.01
Total Assets 10723.77
Total Liabilities 10723.77
Total Equity 9271.57
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.22
Return on Capital (%) 21.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 107.36
Total Assets 8514.11
Total Liabilities 8514.11
Total Equity 7316.69
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.68
Particulars MAR 2024 (Values in Cr)
Net Income 2163.00
Cash from Operations 1637.00
Cash from Investing -269.00
Cash from Financing -799.00
Net change in Cash 193.00
Free Cash Flow 2640.00
Particulars MAR 2023 (Values in Cr)
Net Income 2369.00
Cash from Operations 2932.00
Cash from Investing -2707.00
Cash from Financing -797.00
Net change in Cash -1045.00
Free Cash Flow 3405.00
Particulars MAR 2022 (Values in Cr)
Net Income 3683.50
Cash from Operations 2552.78
Cash from Investing -2194.92
Cash from Financing -532.44
Net change in Cash -815.56
Free Cash Flow 3265.98
Particulars MAR 2021 (Values in Cr)
Net Income 2666.04
Cash from Operations 2591.25
Cash from Investing 75.13
Cash from Financing -34.89
Net change in Cash 1987.17
Free Cash Flow 3501.44
Particulars MAR 2020 (Values in Cr)
Net Income 1819.46
Cash from Operations 1661.17
Cash from Investing -83.47
Cash from Financing -1091.42
Net change in Cash 41.05
Free Cash Flow 2844.38
Particulars MAR 2024 (Values in Cr)
Net Income 2132.00
Cash from Operations 1639.00
Cash from Investing -268.00
Cash from Financing -798.00
Net change in Cash 200.00
Free Cash Flow 2641.00
Particulars MAR 2023 (Values in Cr)
Net Income 2354.00
Cash from Operations 2919.00
Cash from Investing -2707.00
Cash from Financing -796.00
Net change in Cash -1056.00
Free Cash Flow 3391.00
Particulars MAR 2022 (Values in Cr)
Net Income 3676.52
Cash from Operations 2539.95
Cash from Investing -2195.40
Cash from Financing -531.50
Net change in Cash -816.74
Free Cash Flow 3253.62
Particulars MAR 2021 (Values in Cr)
Net Income 2627.87
Cash from Operations 2580.01
Cash from Investing 75.34
Cash from Financing -33.97
Net change in Cash 1988.42
Free Cash Flow 3489.99
Particulars MAR 2020 (Values in Cr)
Net Income 1813.29
Cash from Operations 1654.44
Cash from Investing -81.38
Cash from Financing -1091.25
Net change in Cash 35.84
Free Cash Flow 2837.30
Company Name Price P/E P/B Market Cap 52 Week Low/High
DIVI S LABORATORIES LTD 4520.10 74.86 8.84 119994.45 3300.00 / 4670.20
BLISS GVS PHARMA LTD 110.15 12.05 1.19 1155.28 77.65 / 148.95
CIPLA LTD 1485.15 28.17 4.49 119928.54 1028.00 / 1581.70
FERMENTA BIOTECH LIMITED 229.35 0.00 2.33 675.00 137.10 / 262.00
GLAXOSMITHKLINE PHARMA LT 2570.70 66.32 24.49 43549.21 1376.50 / 2759.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
DIVI S LABORATORIES LTD 4520.10 76.17 8.89 119994.45 3300.00 / 4670.20
AMRUTAJAN HEALTH LTD 738.70 47.47 7.40 2135.63 556.05 / 826.00
ASTRAZENECA PHARMA IND LT 6349.65 106.48 22.29 15874.13 3730.00 / 7550.00
BLISS GVS PHARMA LTD 110.15 15.17 1.16 1155.28 77.65 / 148.95
ABBOTT INDIA LIMITED 27407.65 48.49 15.74 58241.26 21907.45 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 4557.00
  • 26 Days 4547.30
  • 10 Days 4559.30
  • 50 Days 4403.00
  • 12 Days 4563.10
  • 100 Days 4156.00
  • 20 Days 4553.90
  • 200 Days 3785.90
4567.88
PIVOT
First Resistance 4620.02
Second Resistance 4655.23
Third Resistance 4707.37
First Support 4532.67
Second Support 4480.53
Third Support 4445.32
RSI 44.56
MACD 15.79
Commodity Channel Index (CCI) -62.09
ADX 7.93
Williams % R -66.76

Over 1 Month

down

0.89

Over 3 Months

down

23.09

Over 6 Months

down

22.36

Over 1 Year

down

24.23

Over 3 Years

down

-2.03

Over 5 Years

down

22.71

DIVI S LABORATORIES LTD Future

Future: Price

30 May
3901.10
27 Jun
3932.00
25 Jul
3956.95
25 May
0 100 200 300 400 500 600

Discount/Premium

25 Jul
21.55
29 Aug
16.95
25 May
0 1 2 3 4 5 6 7

Active Calls

4000.0
903
3900.0
640
4200.0
364
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

3900.0
339
3800.0
299
3700.0
173
25 Jul
0 500 1000 1500 2000 2500

DIVI S LABORATORIES LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
18.84
Promoter Holdings
51.89
FII
16.15
DII
13.1
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Nilima Prasad Divi Shareholding of Promoter and Promoter Group 5.4E7 20.34
Satchandra Kiran Divi Shareholding of Promoter and Promoter Group 5.4E7 20.34
Sbi Mutual Fund Public Shareholding 1.9681394E7 7.41
Life Insurance Corporation Of India Public Shareholding 1.7853867E7 6.73
Swarna Latha Divi Shareholding of Promoter and Promoter Group 1.4E7 5.27
Divi's Biotech Private Limited Shareholding of Promoter and Promoter Group 8000000.0 3.01
Murali Krishna Prasad Divi Shareholding of Promoter and Promoter Group 7567000.0 2.85
Government Pension Fund Global Public Shareholding 4325737.0 1.63
Axis Mutual Fund Trustee Limited Public Shareholding 4260002.0 1.6
Nippon Life India Trustee Ltd Public Shareholding 2827428.0 1.07
Madhusudana Rao Divi Shareholding of Promoter and Promoter Group 205090.0 0.08
Radhakrishna Rao Divi Shareholding of Promoter and Promoter Group 0.0 0.0

DIVI S LABORATORIES LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-08-11 30.0 Final 2023-08-11 Equity shares 2022-08-11 30.0 Final 2022-08-12 Equity shares 2021-08-17 20.0 Final 2021-08-20 Equity shares 2020-02-25 16.0 Interim 2020-02-26 Equity shares 2019-08-14 16.0 Final 2019-08-17 Equity shares 2018-08-31 10.0 Final 2018-09-04 Equity shares 2017-09-15 10.0 Final 2017-09-19 Equity shares 2016-03-17 10.0 Interim 2016-03-18 Equity shares 2015-08-06 20.0 Final 2015-08-10 Equity shares 2014-07-31 20.0 Final 2014-08-04 Equity shares 2013-07-25 15.0 Final 2013-07-29 Equity shares 2012-07-26 13.0 Final 2012-07-30 Equity shares 2011-06-16 10.0 Final 2011-06-18 Equity shares 2010-07-02 6.0 Final 2010-07-06 Equity shares 2009-06-15 6.0 Final 2009-06-17 Equity shares 2008-06-26 4.0 Final 2008-06-28 Equity shares 2007-03-23 2.0 Interim 2007-03-26 Equity shares 2005-08-11 0.0 Final 2005-08-13 Equity shares
Ex-Date Ex-Bonus Ratio
2015-09-26 2015-09-23 1:1 2009-08-01 2009-07-30 1:1
Ex-Date Old FV NEW FV Record Date
2007-08-03 10.0 2.0 2007-08-10

Divi's Laboratories Limited Overview

Since its inception in 1990, Divis Laboratories Ltd has carved a niche in manufacturing and exporting APIs, intermediates, and Nutraceutical ingredients, catering to the global pharmaceutical and nutraceutical industries. With a portfolio that includes 30 high-volume generic APIs, custom synthesis services for top pharma companies, and a specialised unit for carotenoids in Visakhapatnam, Divis stands out for its extensive range and global reach. The company boasts six multi-purpose manufacturing facilities in Telangana and Visakhapatnam, recognized among the largest API production sites worldwide, with a significant reactor capacity and multiple cGMP and customer quality audits. Offering a diverse product list across various therapeutic categories, Divis Laboratories is a global leader in Naproxen and has a strong international presence with marketing subsidiaries in the USA and Switzerland. The majority of its revenue comes from product sales, heavily weighted towards exports, especially to Europe and North America. Moving forward, Divis is expanding with a new manufacturing site in Kakinada and investing in cutting-edge technologies, underscoring its commitment to innovation and growth in the pharmaceutical sector.

Learn More About Stocks

About DIVI S LABORATORIES LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by DIVI S LABORATORIES LTD

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Divis Laboratories Ltd?

Answer Field

The share price of Divis Laboratories Ltd for NSE is ₹ 4790.6 and for BSE is ₹ 4792.15.

What is the Market Cap of Divis Laboratories Ltd?

Answer Field

The market cap of Divis Laboratories Ltd for NSE is ₹ 12,71,75.40 Cr. and for BSE is ₹ 12,72,16.50 Cr. as of now.

What is the 52 Week High and Low of Divis Laboratories Ltd?

Answer Field

The 52 Week High and Low of Divis Laboratories Ltd for NSE is ₹ 4670.00 and ₹ 3295.30 and for BSE is ₹ 4670.20 and ₹ 3300.00.

How to Buy Divis Laboratories Ltd share?

Answer Field

You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Divis Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 24.23%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7.5 Lacs+ Users

icon-with-text

4.3+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300 Cr MTF Book

icon-with-text
loader